Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 3/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
| ▸ | KRAS | P01116 | 3/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359329 | 0.86 | CYP3A4 (0.36) | CYP3A4ALOX5APFEN1 | |
| SCHEMBL1358134 | 0.86 | ALDH1A1 (0.38) | CYP3A4 | |
| SCHEMBL1348967 | 0.82 | ALDH1A1 (0.35) | CYP3A4EIF2AK4 | |
| SCHEMBL1360375 | 0.82 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL12137040 | 0.81 | RORC (0.37) | EIF2AK4ALOX5APFEN1KRAS | |
| SCHEMBL1359499 | 0.75 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL1358011 | 0.75 | CYP3A4 (0.37) | CYP3A4 | |
| SCHEMBL1359458 | 0.75 | ALOX5AP (0.41) | CYP3A4ALOX5APFEN1JAK1 | |
| SCHEMBL1972033 | 0.74 | CYP3A4 (0.39) | CYP3A4 | |
| SCHEMBL1358409 | 0.74 | ALDH1A1 (0.36) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067442-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-29 | — | — | US | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | CYP3A4 713/4885EIF2AK4 695/4885ALOX5AP 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.